- NAMSA
- About Us
- Account
- Activity
- Careers at NAMSA
- Client Testimonials
- Clinical Training
- Code Analysis and Applications
- Contact Us
- Contract Research Organization Services
- Clinical Research Services
- Medical Device Consulting
- Clinical Trial CRO Consulting
- FDA U.S. Agent Services
- International Medical Device Registration Consulting
- ISO Compliance & Quality Systems Consulting
- Medical Device Clinical Research Staffing
- Medical Device Regulatory Consulting
- Medical Device Strategy Consulting
- Medical Device Validation & Safety Consulting
- Mock Audits
- Medical Device Testing Services
- Our Therapeutic Expertise
- Anesthesia & Respiratory CRO
- Cardiology CRO
- Dental CRO
- Dermal Wound Care & Dermatology CRO
- Diabetic Care CRO
- Diagnostic Imaging & Radiology CRO
- Ear, Nose & Throat CRO
- Gastroenterology & Bariatrics CRO
- General Plastic Surgery CRO
- Hematology & Oncology CRO
- IVD & Companion Diagnostics CRO
- Neurosurgery & Spinal Surgery CRO
- Obstetrics & Gynecology CRO
- Ophthalmology CRO
- Orthopedics CRO
- Peripheral Vascular CRO
- Regenerative Medicine CRO
- Testing
- Biocompatibility Testing Services
- Biological Safety Services
- Cleaning Study Development & Execution
- Environmental Monitoring Services
- Histopathology Services
- Long-Term or Accelerated Shelf Life Testing
- Material Characterization & Analytical Chemistry
- Medical Device Risk Assessment
- Method Development & Validation Services
- Other Microbiology Testing Services
- Packaging Validation Services
- Particulate Analysis Services
- Physician Training
- Preclinical Studies
- Sterilization Validation Services
- Validation for Reprocessed Medical Devices
- Cornerstone Draft
- courses-dashboard
- Do you know who is doing your biocompatibility testing?
- EU MDR & IVDR Planning Resources
- European Union’s General Data Protection Regulation Frequently Asked Questions – Clients
- European Union’s General Data Protection Regulation Frequently Asked Questions – Vendors
- event registration
- event replay
- Events
- Health Economics Analysis
- IVD & Companion Diagnostics Expertise
- IVD CRO OVERVIEW
- IVD EXPERTISE
- IVD SERVICES
- live-event
- login
- Make an Appointment
- Materials Characterization Matrix
- Medical Device Reimbursement Consulting
- Medical Policy Research and Coverage Advocacy
- Members
- Membership List
- MRO and CRO Comparison
- NAMSA BIOCOMPATIBILITY STRATEGY NAVIGATOR
- NAMSA Blog: News, Trends & Education
- NAMSA Cookies Policy
- NAMSA EU – U.S. and Swiss – U.S. Privacy Shield
- NAMSA France
- NAMSA Germany
- NAMSA Latin America
- NAMSA Launches New Analytical Services Laboratory in Germany
- NAMSA MRO Summits
- NAMSA Purchasing Terms and Conditions
- NAMSA Test Navigator
- NAMSA’s Client Standard Terms and Conditions
- oneclick-registration
- Our Accreditations & Certifications
- Our Global CRO Locations
- Our History: From CRO to MRO
- Our Values: Integrity, Sustainability, Efficiency
- Privacy Policy
- Product Adoption Support
- Product Development Strategy
- Protected Content
- Protected Content
- Registration
- Registration Cancelled
- Registration Checkout
- Resources
- Education
- Events
- Glossary of Terms
- Medical Device Development & Regulatory Webinars
- Podcasts
- Biocompchatibility – CSI: Cracking the Case
- Biocompchatibility – Editor Chat: Biocompatibility and Performance of Medical Devices
- Biocompchatibility – Extractions: The How and Why
- Biocompchatibility – NAMSA Training Series: Live from Frankfurt
- Biocompchatibility – NAMSA Training Series: Live from Philadelphia
- Biocompchatibility – Welcome
- Biocompchatibility – Welcome to NAMSA: Lisa Olson
- Resource Library: Information for Medical Device Developers
- Useful Links for Medical Device Manufacturers
- Sample Submission Forms
- Site Map
- Sterilization Products
- Store
- Subscribe to the NAMSA Network
- Terms of Use
- test
- Test Slider
- Test webinar
- thank you
- Thank You
- Thank You for Contacting NAMSA!
- Thank You for Registering
- Thank-You Page
- Transactions
- Understanding Europe’s MDR and IVDR
- Webinar Countdown (Mandatory page, please do not modify or delete [EasyWebinarPlugin])
- Webinar Error (Mandatory page, please do not modify or delete [EasyWebinarPlugin])
- What Is A Medical Research Organization?
- Medical Research Organization
- Our Strategic Partners
- Stage 1 Medical Device Development Services: Concepting & Feasibility
- Stage 2 Medical Device Development Services: Design Validation/Preclinical Testing
- Stage 3 Medical Device Development Services: Clinical
- Stage 4 Medical Device Development Services: Market Approval
- Stage 5 Medical Device Development Services: Post-Market
- Asian Market
- Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
- CFDA Releases Technical Guidelines for the Acceptance of Overseas Clinical Trial Data of Medical Devices
- CFDA Releases “Amendments to the Regulations on the Supervision and Administration of Medical Devices” Exposure Draft
- Japan’s “Ninsho Kijun” Regulatory Approval Pathway
- New Medical Device Classification Catalog Issued by the CFDA
- Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
- China Releases Regulations for the Supervision and Administration of Medical Devices (No. 680)
- Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
- CFDA Announces “Administrative Measures on Communication with Applicants for the Technical Evaluation of Medical Device (Trial)"
- Ensuring the Confidentiality of Chinese Medical Device Manufacturers
- Focus on Japan Series: Part I - Important Factors for Medical Device Development in Japan
- Guidelines for Medical Device Development in Japan
- CFDA Issues Announcement on Medical Device Priority Approval Procedures
- CFDA Provisions for Medical Device Adverse Event Monitoring and Re-evaluation
- The Three Pathways to Medical Device Registration in Japan
- CFDA Oversea GMP Inspections
- New Marketing Application Procedure for Combination Products in Japan
- CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
- Definition of “Regenerative Medical Products” in Japanese Law Has Been Revised
- CFDA is Collecting Comments on Clinical Exemption Catalogue
- The Strategy of SAKIGAKE and How It Applies to Medical Devices
- Regenerative Medicine-Related Organizations and Activities in Japan
- CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- Steady Growth for China's Medical Device Fast Track Process
- PMDA Submission Strategy and CRO Limitations, Part 1
- China Acceptance of Foreign Biocompatibility Reports
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- China Regulation Updates
- CFDA Regulation Creates Changes in Chinese Regulatory Landscape
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- NAMSA China Expands Expertise and Services
- Emerging Markets Theater - Life Science Alley Conference
- Chemical Characterization
- Clinical
- MDR Update: Draft Corrigenda Published Outlining Positive Impact to Class I Manufacturers and Up-Classification Rules
- Key Requirements of Post-Market Surveillance under IVDR
- IVDR Technical Documentation: 5 Critical Parameters of Change You Must Understand
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
- Update on FDA’s Clinical Trials Program for Medical Devices
- NAMSA White Paper: Risk-Based Monitoring: Exploring the Clinical Site Experience
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- Medical Device Clinical Trials: SAE reporting requirements in Germany and Austria
- Medical Device Development: Clinical Studies, Part 2
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA White Paper: Risk-Based Monitoring: Considerations for Clinical Implementation
- Medical Device Development: Clinical Studies, Part 1
- NAMSA White Paper: FDA Pre-Submission or Q-Sub Program
- NAMSA White Paper: Risk-Based Monitoring: Setting up the Structure for a Systematic Approach
- NAMSA and Fortuna Clinical Form Strategic Relationship
- NAMSA White Paper: Human Factors Studies in Medical Device Reprocessing
- NAMSA White Paper: Risk-Based Monitoring: A Cognizant Approach
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
- Additional Information You Should Know Before Performing a Clinical Study
- Obstacles in European Clinical Trials
- Differences and Similarities in Investigator Selection Between the US and EU
- Things to Consider When Selecting a Clinical Investigator
- Selecting a CRO for Clinical Research
- Selecting an Optimal Study Site in the EU
- China Regulation Updates
- Conducting a Clinical Study in the US
- Remote Monitoring in Clinical Testing
- Responsibilities of an Authorized Representative and US Agent
- Updating a Clinical Evaluation Report (CER)
- The Need for an Agent for Clinical Trials in the US
- The Need for an Authorized Representative for Clinical Trials in the EU
- Insights for Clinical Management
- Meet with NAMSA on the Road
- FDA Gives New IVD Guidance
- Emerging Markets Theater - Life Science Alley Conference
- Developing a European First-In-Human (FIH) Study
- Remote Training Seminars Now Offered By NAMSA
- Consulting
- MDR Update: Draft Corrigenda Published Outlining Positive Impact to Class I Manufacturers and Up-Classification Rules
- Key Requirements of Post-Market Surveillance under IVDR
- IVDR Technical Documentation: 5 Critical Parameters of Change You Must Understand
- MDCG ISSUES Guidance on Summary of Safety and Clinical Performance under the Medical Device Regulation (MDR)
- Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
- EU IVDR: Understanding the New QMS Requirements
- Three Essentials for Smart IVD Clinical Trial Design
- FDA CDRH: New Organizational Structure Effective May 1, 2019
- Draft Corrigenda for EU MDR and IVDR Released
- EMA Issues Q&A Regarding Impact of MDR, Article 117
- EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
- UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
- EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
- Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
- FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
- EU Commission & MDCG Release New MDR & IVDR Guidance Documents
- FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
- Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
- FDA Announces FY19 User Fees
- EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- Mid-Year FDA Regulation & Guidance Review
- FDA Issues New Draft Guidance Document for Pre-Submissions
- EU MDR and IVDR Compliance Planning Resources
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
- Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
- Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
- ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
- Japan’s “Ninsho Kijun” Regulatory Approval Pathway
- Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
- Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
- Focus on Japan Series: Part II - Understanding the Designated Marketing Authorization (D-MAH) Status for Foreign Device Manufacturers
- NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
- FDA Warning Letters for Non-US Manufacturers
- FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- New Marketing Application Procedure for Combination Products in Japan
- CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
- The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
- FDA Finalizes Biocompatibility Guidance for Medical Devices
- FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
- CFDA is Collecting Comments on Clinical Exemption Catalogue
- Human Factors / Usability Engineering in Product Design and Development
- Is 2016 The Year That CMS Starts Fining Sunshine Act Violators?
- Unannounced Notified Body Audit
- FDA Clarifies Policy for Color Additives in Medical Devices
- Regenerative Medicine-Related Organizations and Activities in Japan
- CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- ISO 13485:2016 - Medical devices – Quality management systems – Requirements for regulatory purposes
- The Importance of Applying Human Factors and Usability Engineering to Medical Devices
- Steady Growth for China's Medical Device Fast Track Process
- PMDA Submission Strategy and CRO Limitations, Part 1
- Regulatory
- The Evolution of the Accreditation Scheme for Conformity Assessment (ASCA) for Medical Device Premarket Approval
- MDR Update: Draft Corrigenda Published Outlining Positive Impact to Class I Manufacturers and Up-Classification Rules
- Key Requirements of Post-Market Surveillance under IVDR
- IVDR Technical Documentation: 5 Critical Parameters of Change You Must Understand
- MDCG ISSUES Guidance on Summary of Safety and Clinical Performance under the Medical Device Regulation (MDR)
- Chinese State Drug Administration Releases ‘Notice on the Implementation of Electronic Declaration of Medical Device Registration’
- EU IVDR: Understanding the New QMS Requirements
- FDA CDRH: New Organizational Structure Effective May 1, 2019
- Draft Corrigenda for EU MDR and IVDR Released
- EMA Issues Q&A Regarding Impact of MDR, Article 117
- EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
- UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
- EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
- Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
- FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- EU Commission & MDCG Release New MDR & IVDR Guidance Documents
- FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
- Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
- FDA Announces FY19 User Fees
- EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- Mid-Year FDA Regulation & Guidance Review
- FDA Issues New Draft Guidance Document for Pre-Submissions
- EU MDR and IVDR Compliance Planning Resources
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
- Japan’s PMDA to Raise Medical Device and IVD Registration User Fees Beginning April 2018
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- CFDA Releases Technical Guidelines for the Acceptance of Overseas Clinical Trial Data of Medical Devices
- EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
- Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
- ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
- CFDA Releases “Amendments to the Regulations on the Supervision and Administration of Medical Devices” Exposure Draft
- Japan’s “Ninsho Kijun” Regulatory Approval Pathway
- Brexit and the Impact on UK Medical Device Operations
- The Importance of Human Factors & Usability Engineering in Medical Devices
- UK MHRA Publishes Guide to the New EU Medical Device and IVD Regulations
- New Medical Device Classification Catalog Issued by the CFDA
- The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
- Japan’s PMDA Consultation Offering: A Beneficial Resource for Streamlined Device Approval
- EU MDR Poses Significant Changes for Importers and Distributors
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- Focus on Japan Series: Part IV - Streamlining the Quality Management System Approval Process
- China Releases Regulations for the Supervision and Administration of Medical Devices (No. 680)
- Risk: An Emerging Driver for New Regulatory Requirements
- Focus on Japan Series: Part III - Registering Facilities under Foreign Manufacturer Accreditation (FMA)
- CFDA Announces “Administrative Measures on Communication with Applicants for the Technical Evaluation of Medical Device (Trial)"
- MDR Transition Timelines for Legacy Medical Devices - Not without Risks and Undue Burden
- Good News for Industry? How the Proposed FDA Class II Device Exemptions Will Impact Medical Device Manufacturers
- EU Parliament Votes to Institute the New IVDR and MDR Regulations; Transition Period Expected to Begin on June 1, 2017
- Why Regional Reimbursement Strategies Could Be Right For Medtech
- France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
- Focus on Japan Series: Part II - Understanding the Designated Marketing Authorization (D-MAH) Status for Foreign Device Manufacturers
- Planning for Success: UDI Requirements Under the EU MDD/MDR
- Ensuring the Confidentiality of Chinese Medical Device Manufacturers
- 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
- Focus on Japan Series: Part I - Important Factors for Medical Device Development in Japan
- Important Considerations for Labelling of Medical Devices Under the New EU MDR
- Guidelines for Medical Device Development in Japan
- Clinical Trials for Innovative Devices: Concurrent Review by FDA/CMS Leads to Time and Cost Efficiencies
- CFDA Issues Announcement on Medical Device Priority Approval Procedures
- CFDA Provisions for Medical Device Adverse Event Monitoring and Re-evaluation
- The Three Pathways to Medical Device Registration in Japan
- ISO 13485:2016 and Risk Management
- Do I Need to Submit a New 510(k)?
- CFDA Oversea GMP Inspections
- FDA Warning Letters for Non-US Manufacturers
- FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
- Update on FDA’s Clinical Trials Program for Medical Devices
- New Marketing Application Procedure for Combination Products in Japan
- CFDA Releases Notice Regarding GSP Compliance for Medical Device Manufacturers
- The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
- FDA Finalizes Biocompatibility Guidance for Medical Devices
- Definition of “Regenerative Medical Products” in Japanese Law Has Been Revised
- FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
- CFDA is Collecting Comments on Clinical Exemption Catalogue
- Human Factors / Usability Engineering in Product Design and Development
- The Strategy of SAKIGAKE and How It Applies to Medical Devices
- New Pre-Market Scrutiny Process for High-Risk Products in Europe
- Industry Survey: FDA's Focus on Early Feasibility Studies
- Unannounced Notified Body Audit
- FDA Clarifies Policy for Color Additives in Medical Devices
- Regenerative Medicine-Related Organizations and Activities in Japan
- CFDA and NHFPC Jointly Issue Decree No. 25 The Good Clinical Practice for Medical Devices
- PMDA Submission Strategy and CRO Limitations, Part 2
- CFDA Authenticity Verification of Clinical Trial Data for Medical Device Kick Off
- ISO 13485:2016 - Medical devices – Quality management systems – Requirements for regulatory purposes
- The Importance of Applying Human Factors and Usability Engineering to Medical Devices
- Steady Growth for China's Medical Device Fast Track Process
- PMDA Submission Strategy and CRO Limitations, Part 1
- Upcoming UDI Requirements and 2016 Compliance Dates for Labelers of Class II Medical Devices
- China Acceptance of Foreign Biocompatibility Reports
- Medical Device Development: Post-Market
- Medical Device Development: Market Approval
- Medical Device Development: Clinical Studies, Part 2
- NAMSA White Paper: Risk-Based Monitoring: Considerations for Clinical Implementation
- Medical Device Development: Clinical Studies, Part 1
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Medical Device Development: Concept and Feasibility, Part 2
- Medical Device Development: Concept and Feasibility, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- Impacts and Obstacles of Innovation in Medical Devices
- FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
- Emerging and Re-Emerging Markets : How to Navigate Innovation Through Global Regulatory Approvals
- Additional Information You Should Know Before Performing a Clinical Study
- Examining the Progress of the Ongoing Revision of the Medical Device Directive
- Moving From In Vitro to In Vivo: What Happens Next?
- Differences and Similarities in Investigator Selection Between the US and EU
- Things to Consider When Selecting a Clinical Investigator
- De Novo Classification Process
- FDA Guidance on Exemptions for Custom Devices
- Selecting a CRO for Clinical Research
- Selecting an Optimal Study Site in the EU
- Updated German Legislation for Medical Devices
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- China Regulation Updates
- Conducting a Clinical Study in the US
- New FDA Regulations on Laboratory-Developed Tests
- Responsibilities of an Authorized Representative and US Agent
- Updating a Clinical Evaluation Report (CER)
- Bringing a Novel Medical Device or IVD to Market
- The Need for an Agent for Clinical Trials in the US
- EU Borderline Classification Manual Update
- The Need for an Authorized Representative for Clinical Trials in the EU
- Revised Code of Conduct for Notified Bodies
- Update on the New EU IVD and Medical Device Regulations
- Informed Consent - Time for Change
- Insights for Clinical Management
- Engaging the Best Notified Body to Certify Your Device in the EU
- Meet with NAMSA on the Road
- The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
- Unique Device Identifier Required for Class III Medical Devices
- NAMSA Speakers Around the Globe
- Optimizing Your Journey on the IDE Approval Pathway: The FDA Pre-Submission Program
- CFDA Regulation Creates Changes in Chinese Regulatory Landscape
- New FDA Guidance Regarding CLIA Categorization Process for IVDs
- Final Pre-Submission Guidance Issued by FDA
- Chinese Medical Device Market Continues to Grow
- FDA Gives New IVD Guidance
- NAMSA China Expands Expertise and Services
- New Acceptance Review Processes for 510(k)s and PMAs
- Remote Training Seminars Now Offered By NAMSA
- European Market
- MDR Update: Draft Corrigenda Published Outlining Positive Impact to Class I Manufacturers and Up-Classification Rules
- Key Requirements of Post-Market Surveillance under IVDR
- IVDR Technical Documentation: 5 Critical Parameters of Change You Must Understand
- NAMSA Expands European Medical Device Testing Solutions with DAkkS DIN ISO/IEC 17025:2018 Accreditation in Germany
- MDCG ISSUES Guidance on Summary of Safety and Clinical Performance under the Medical Device Regulation (MDR)
- Draft Corrigenda for EU MDR and IVDR Released
- EMA Issues Q&A Regarding Impact of MDR, Article 117
- EU Issues Q&A Document to Provide Further Analysis of Potential No-Deal Brexit
- UK MHRA Releases Contingency Legislation Covering Regulation of Medical Devices in Brexit ‘No Deal’ Scenario
- EU Commission Updates Website to Provide Additional MDR and IVDR Planning Resources
- Renewal Timelines Quickly Approaching for Medical Device Directive (MDD:M5) CE Mark Certificates
- EU Commission & MDCG Release New MDR & IVDR Guidance Documents
- Effective Implementation of EN ISO 14971 Medical Device Risk Management Standard
- EU Commission Issues Supplementary Guidance Information for CE Marks Under MDR & IVDR
- EU MDR and IVDR Compliance Planning Resources
- CE Marking of Digital Health Technologies: Stricter Rules for Medical Device Software under the EU MDR
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- EU Commission Issues “Notice to Stakeholders: Withdrawal of the United Kingdom and EU Rules in the Field of Industrial Products”
- NAMSA Expands Medical Device Testing Services in Germany to Increase Access to Accelerated Product Development
- NAMSA Launches German Website to Support Europe’s Largest Medical Device Marketplace
- Brexit and the Impact on UK Medical Device Operations
- The Importance of Human Factors & Usability Engineering in Medical Devices
- UK MHRA Publishes Guide to the New EU Medical Device and IVD Regulations
- EU MDR Poses Significant Changes for Importers and Distributors
- Risk: An Emerging Driver for New Regulatory Requirements
- MDR Transition Timelines for Legacy Medical Devices - Not without Risks and Undue Burden
- EU Parliament Votes to Institute the New IVDR and MDR Regulations; Transition Period Expected to Begin on June 1, 2017
- France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
- Planning for Success: UDI Requirements Under the EU MDD/MDR
- 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
- Important Considerations for Labelling of Medical Devices Under the New EU MDR
- ISO 13485:2016 and Risk Management
- FDA Warning Letters for Non-US Manufacturers
- MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
- The New European MDR – Harmonization Effort with International Regulatory Requirements for Medical Devices
- Human Factors / Usability Engineering in Product Design and Development
- New Pre-Market Scrutiny Process for High-Risk Products in Europe
- Unannounced Notified Body Audit
- Medical Device Clinical Trials: SAE reporting requirements in Germany and Austria
- Obstacles in European Clinical Trials
- Differences and Similarities in Investigator Selection Between the US and EU
- Selecting a CRO for Clinical Research
- Selecting an Optimal Study Site in the EU
- Updated German Legislation for Medical Devices
- Responsibilities of an Authorized Representative and US Agent
- The Need for an Agent for Clinical Trials in the US
- EU Borderline Classification Manual Update
- The Need for an Authorized Representative for Clinical Trials in the EU
- Revised Code of Conduct for Notified Bodies
- Update on the New EU IVD and Medical Device Regulations
- Engaging the Best Notified Body to Certify Your Device in the EU
- CFDA Regulation Creates Changes in Chinese Regulatory Landscape
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- Emerging Markets Theater - Life Science Alley Conference
- New EU Medical Device Legislation Proposal
- Developing a European First-In-Human (FIH) Study
- FDA
- The Evolution of the Accreditation Scheme for Conformity Assessment (ASCA) for Medical Device Premarket Approval
- FDA CDRH: New Organizational Structure Effective May 1, 2019
- FDA Shifts 510(K) Paradigm, Announces Transformative Steps to Modernize 510(k) Program
- FDA CDRH Reorganization: Faster Reviews for Medical Device Manufacturers?
- FDA Announces FY19 User Fees
- Mid-Year FDA Regulation & Guidance Review
- FDA Issues New Draft Guidance Document for Pre-Submissions
- Obtaining Actionable FDA Feedback: How to Develop Targeted Questions for Pre-Submission Meetings
- ISO 13485:2016 - Effective Preparation and Implementation of Medical Device Quality Management Systems
- White Paper: Utilizing Biological Risk Assessments and Chemical Characterization to Reduce Medical Device Development Timelines
- The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
- Good News for Industry? How the Proposed FDA Class II Device Exemptions Will Impact Medical Device Manufacturers
- Why Regional Reimbursement Strategies Could Be Right For Medtech
- France Imposes New Registration Requirement for Implantable and Class III Medical Device Manufacturers
- Planning for Success: UDI Requirements Under the EU MDD/MDR
- 2017 Medical Device Outlook: Five Potential Impacts to Global Device Organizations
- Clinical Trials for Innovative Devices: Concurrent Review by FDA/CMS Leads to Time and Cost Efficiencies
- Do I Need to Submit a New 510(k)?
- FDA Factors to Consider Regarding Benefit - Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- Update on FDA’s Clinical Trials Program for Medical Devices
- FDA Finalizes Biocompatibility Guidance for Medical Devices
- FDA Issues ‘Leap-Frog’ Guidance for 3D-Printed Medical Devices
- Industry Survey: FDA's Focus on Early Feasibility Studies
- FDA Clarifies Policy for Color Additives in Medical Devices
- The Importance of Applying Human Factors and Usability Engineering to Medical Devices
- Upcoming UDI Requirements and 2016 Compliance Dates for Labelers of Class II Medical Devices
- Medical Device Development: Post-Market
- Medical Device Development: Market Approval
- Traceability in Device Design, Development, and Distribution
- NAMSA White Paper: FDA Pre-Submission or Q-Sub Program
- NAMSA White Paper: Human Factors Studies in Medical Device Reprocessing
- NAMSA White Paper: Risk-Based Monitoring: A Cognizant Approach
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- FDA Draft Guidance on Acceptance of Medical Device Clinical Data from Studies Conducted Outside the US
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- Differences and Similarities in Investigator Selection Between the US and EU
- Package Validation
- De Novo Classification Process
- FDA Guidance on Exemptions for Custom Devices
- Medibio Has Appointed NAMSA to Assist with Trial Design and Regulatory Discussion with the US FDA
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- New FDA Regulations on Laboratory-Developed Tests
- The Need for an Agent for Clinical Trials in the US
- Informed Consent - Time for Change
- FDA Guidelines for Social Media Posts with Character Limitations
- The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- Unique Device Identifier Required for Class III Medical Devices
- Optimizing Your Journey on the IDE Approval Pathway: The FDA Pre-Submission Program
- Reusable Medical Device
- Final Pre-Submission Guidance Issued by FDA
- FDA to Propose Guidelines For Interoperable Medical Devices
- FDA Gives New IVD Guidance
- New Acceptance Review Processes for 510(k)s and PMAs
- FDA Regulation of Mobile Medical Applications
- Industry Reposts
- MEDDEV 2.7.1 Revision 4 – Stricter Requirements for Clinical Evaluation Reports
- Is 2016 The Year That CMS Starts Fining Sunshine Act Violators?
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Updated German Legislation for Medical Devices
- FDA Guidelines for Social Media Posts with Character Limitations
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- New FDA Guidance Regarding CLIA Categorization Process for IVDs
- Final Pre-Submission Guidance Issued by FDA
- FDA to Propose Guidelines For Interoperable Medical Devices
- IVD
- Microbiology
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- White Paper: Utilizing Biological Risk Assessments and Chemical Characterization to Reduce Medical Device Development Timelines
- NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- Introducing NAMSA Connect
- Reusable Medical Device
- NAMSA Irvine Facility Expands
- MRO
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- The Value of Randomized Pilot Studies in Demonstrating Patient Safety and Efficacy
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Medical Device Development: Concept and Feasibility, Part 2
- Medical Device Development: Concept and Feasibility, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- NAMSA White Paper: MedTech Outsourcing: Is the Past Any Indication of the Future?
- China Regulation Updates
- Informed Consent - Time for Change
- Engaging the Best Notified Body to Certify Your Device in the EU
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- The FDA Acceptance Review and Refuse To Accept Processes for PMAs and 510(k)s
- Independent Assessment of FDA Device Review Program Results in 11 Recommendations
- Introducing NAMSA Connect
- NAMSA’s Cell Culture Capabilities
- Unique Device Identifier Required for Class III Medical Devices
- NAMSA's Anatomic Program
- Reusable Medical Device
- NAMSA China Expands Expertise and Services
- NAMSA Irvine Facility Expands
- News
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- NAMSA Expands Service Network Expertise into Costa Rica
- NAMSA Expands Service Network Expertise into Brazil and Mexico
- NAMSA Announces Divestiture of its Sterility Assurance Products Division
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- Medibio Has Appointed NAMSA to Assist with Trial Design and Regulatory Discussion with the US FDA
- NAMSA Symposium Coming to China
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- Introducing NAMSA Connect
- Agenda Announced for Germany Symposium
- NAMSA Announces 2014 Remote Training Series Calendar
- The 2014 BPMDS Kicks Off In Germany
- NAMSA Acquires Medvance LTD., Expanding European Presence and Clinical and Consulting Services
- NAMSA Adds BMP-2 Assay to a Comprehensive Breadth of Solutions for DBM Testing
- NAMSA China Expands Expertise and Services
- Emerging Markets Theater - Life Science Alley Conference
- NAMSA Partners with Medipert
- NAMSA Irvine Facility Expands
- Remote Training Seminars Now Offered By NAMSA
- NAMSA to Sponsor and Speak at Biocompatibility and Performance of Medical Device Symposium in Minneapolis
- NAMSA Sponsoring Conference on Best Practices for Biocompatibility and Performance for Medical Devices
- NAMSA Expands State-Of-The-Art Laboratory in Lyon, France
- NAMSA Acquires The Integra Group, Expanding Imaging and Clinical Services
- NAMSA Rebrands Business Unit in France
- NAMSA Expands ICP Offering
- NAMSA Opens Frankfurt Office to Provide Clinical Trial and Regulatory Support
- NAMSA Renames Acquisition
- NAMSA to Expand Laboratory Facilities
- NAMSA Continues to Expand Materials Testing Capabilities
- 2012 Fee Schedule Update
- Press Release
- NAMSA Expands European Medical Device Testing Solutions with DAkkS DIN ISO/IEC 17025:2018 Accreditation in Germany
- NAMSA Recognized as Leading Medical Device CRO for Third Consecutive Year by Life Science Leader
- NAMSA Announces Acquisition of Reimbursement Strategies, LLC, Expands Medical Device Development Portfolio
- NAMSA® Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
- NAMSA® Launches Market Intelligence Report on Global Medical Device Clinical Outsourcing Trends
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA® Launches "Uniquely IVD" Development Services to Expedite in vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers
- NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader
- NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe
- NAMSA Expands Medical Device Testing Services in Germany to Increase Access to Accelerated Product Development
- NAMSA Launches German Website to Support Europe’s Largest Medical Device Marketplace
- NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
- NAMSA Launches Japanese Website to Support Increased Demand for Medical Device Development Services
- NAMSA Celebrates 50 Years of Scientific Innovation in the Medtech Industry
- NAMSA Recognized as a Premier International CRO by Life Science Leader
- NAMSA and NAGLREITER Partner to Provide Innovative Development Solution to Global Medical Device Manufacturers
- NAMSA Broadens Global Reach of Medical Device Development Summits to Increase Access to Industry Experts
- NAMSA Expands Medical Device Clinical and Consulting Services Presence in Minneapolis to Accommodate Growth
- NAMSA Expands Service Offering in China with Opening of Shanghai Laboratory
- NAMSA Expands Service Network Expertise into Costa Rica
- NAMSA Expands Service Network Expertise into Brazil and Mexico
- NAMSA Announces Divestiture of its Sterility Assurance Products Division
- NAMSA Expands Service Offering Expertise Into South America
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- NAMSA Acquires Medvance LTD., Expanding European Presence and Clinical and Consulting Services
- NAMSA Acquires The Integra Group, Expanding Imaging and Clinical Services
- Packaging & Stability
- Ready for DuPont’s Transition Tyvek®? NAMSA Can Help!!
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Recommendations for Designing Studies for the Validation of Reprocessing Instructions
- Package Validation
- NAMSA Shelf Life Validation
- Preclinical
- China Acceptance of Foreign Biocompatibility Reports
- NAMSA Expands Service Offering Expertise Into South America
- Traceability in Device Design, Development, and Distribution
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- NAMSA and Fortuna Clinical Form Strategic Relationship
- Infographic: Common Mistakes in the Medical Device Development Continuum
- NAMSA White Paper: Joining Preclinical and Clinical Development: A Practical Approach to Reducing Medical Device Timelines
- Announcing Construction of New Preclinical Laboratory for Medical Device Research in Shanghai, China
- Evaluation of Tissue Regeneration as Support in Translative Research
- Advances in Medical Device Materials. Part 2: Synthetic Collagen Fibers & Trimethylene Carbonate/Lactide/Glycolide Polymers
- Advances in Medical Device Materials. Part 1: Polycarbonate Resins
- The Basics of Bone Implantation, Part 3: Evaluation of a Bone Implantation Study
- UPLC/MS
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- The Basics of Bone Implantation, Part 2: Designing an Effective Bone Implantation Study
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- New FDA Regulations on Laboratory-Developed Tests
- A Recent Human Anatomic Study Conducted with NAMSA
- Insights for Clinical Management
- NAMSA Receives AAALAC Accreditation for Preclinical Facility in Minnesota
- Introducing NAMSA Connect
- NAMSA’s Cell Culture Capabilities
- Toxicology
- NAMSA Launches Online Biocompatibility Strategy Application to Streamline Development Efforts for Global Medical Device Manufacturers
- NAMSA Announces New Online Test Selection Tool to Support Global Medical Device Manufacturers
- Medical Device Development: Design Validation and Preclinical, Part 2
- Medical Device Development: Design Validation and Preclinical, Part 1
- Infographic: Common Mistakes in the Medical Device Development Continuum
- Evaluation of Tissue Regeneration as Support in Translative Research
- The Basics of Bone Implantation, Part 3: Evaluation of a Bone Implantation Study
- Don Palme at MD&M Minneapolis
- Moving From In Vitro to In Vivo: What Happens Next?
- The Basics of Bone Implantation, Part 2: Designing an Effective Bone Implantation Study
- The Basics of Bone Implantation, Part 1: Why Bone Implantation?
- New Developments in FDA Biocompatibility Requirements for Personal Lubricants
- Insights for Clinical Management
- Introducing NAMSA Connect
- NAMSA Speakers Around the Globe
- NAMSA's Anatomic Program
- Continuous Preclinical Monitoring in Medical Device Studies
- USP Class Testing
- Chinese Medical Device Market Continues to Grow
- The 2014 BPMDS Kicks Off In Germany
- NAMSA Adds BMP-2 Assay to a Comprehensive Breadth of Solutions for DBM Testing